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Background: Dementia is generally considered an irreversible process of cognitive decline that can be caused by
different neurodegenerative diseases. However, in some cases, dementia is caused by a non-neurodegenerative
disease, such as an affective disorder. In these cases, the dementia can be reversible. Nevertheless, cognitive symptoms
due to an affective disorder are often difficult to distinguish from a depressed mood due to a neurodegenerative
disease. Especially in elderly patients with a history of affective disorder, a potentially reversible cause can be missed.
Case presentation: We describe a 60-year-old white woman with bipolar disorder, depressive symptoms, a movement
disorder and severe cognitive impairment, in whom a neurodegenerative disease was seriously considered. She was
referred to our clinic for further investigation because initial treatment of the depressive episode with antidepressants,
mood stabilizers and electroconvulsive therapy (ECT) had not been successful. However, despite extensive evaluation,
we could not find evidence for a neurodegenerative disease and the patient mostly recovered after discontinuation of
different psychotropic medications and treatment with nortriptyline.
Conclusions: Our case shows that improvement of severe cognitive impairment in individual cases is possible. In our
opinion, this underlines the necessity of a careful re-evaluation of the patient’s symptoms at presentation and the
course of the disease as well as a critical review of the prescribed medications.
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Dementia is a syndrome of cognitive deficits that is
generally characterised by impairment in short- and
long-term memory, and is often associated with impair-
ment in abstract thinking or judgment, other disturbances
of higher cortical function such as aphasia or apraxia,
or personality change [1]. The cognitive deficits are
severe enough to interfere significantly with work or
usual social activities or relationships with others, and
are not only present during a delirium. Dementia is most
commonly caused by a neurodegenerative disease, such as
Alzheimer’s disease, vascular dementia or Parkinson’s
disease [2]. Therefore, dementia is generally considered
an irreversible process of cognitive decline.* Correspondence: g.j.izaks@umcg.nl
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unless otherwise stated.Since more than a century, it has been known that
dementia can also be caused by non-neurodegenerative
diseases and in some cases, can even be reversible if the
underlying cause is adequately treated. One of the firsts
reports was about the successful treatment of dementia
due to neurosyphilis [3], but (partially) reversible de-
mentia can also be caused by several other diseases.
Infections, metabolic disturbances, brain tumors, nor-
mal pressure hydrocephalus, subdural hematoma, and
drugs are well known examples [4,5].
Among the most prevalent diseases that can cause revers-
ible dementia are affective disorders. Affective disorders
include major depressive disorder, bipolar disorder, dys-
thymic disorder and cyclothymic disorder [1]. In Europe,
the lifetime (combined) prevalence of affective disorders is
approximately 14%. Of these, a major depressive disorder is
the most frequent with a lifetime prevalence of 12% and a
12-month prevalence of 4%. The 12-month prevalence of
bipolar disorder accounts for 0.7%-1.1% [6-8]. These results
have been confirmed in several studies.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Change in Mini-Mental State Examination score [18]
during treatment.
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cases, dementia is caused by a major depressive disorder
[5]. Probably, this percentage is higher in persons aged
<70 years. A study from the Rochester Epidemiology
Project found that 3% of the patients aged <70 had
dementia due to mental illness such as schizoaffective
disorder and major depressive disorder [9]. It has also
been suggested that in patients with dementia due to a
major depressive disorder, the dementia may be com-
pletely reversible in 30% of the patients [4]. However,
up till now, many questions remain unanswered. For
example, little is known about the severity of cognitive
deficits in patients with reversible dementia due to a
depressive disorder, or whether the severity of these
deficits determine the reversibility. Also, it is still
unclear if reversibility of the cognitive deficits is
dependent on the type of affective disorder. Although
some studies report improvement of cognitive deficits
after successful treatment of patients with a major de-
pressive disorder with psychotic features [10,11], other
studies report persisting cognitive deficits in patients
with a bipolar disorder [12-14].
Bipolar disorders are generally divided into two
groups. Patients with type 1 bipolar disorder have
experienced at least one manic episode that may have
been preceded or may be followed by one or more
hypomanic or depressive episodes [15]. In contrast,
patients with type 2 bipolar do not experience full
manic episodes but have experienced at least one hypo-
manic episode in addition to one or more depressive epi-
sodes [15]. Between manic and depressive episodes, these
patients are considered to be euthymic [15]. In the last
decade, there has been a particular interest in cognitive
deficits in patients with a bipolar disorder [12-14]. Several
studies report a similar pattern and severity of cognitive
deficits in manic and depressive episodes and euthymic
phases [12,14]. Interestingly, however, cognitive deficits
have been found to be related to the duration of the bipo-
lar disorder and the total number of manic and depressive
episodes [12,13].
The diagnosis of dementia has great implications for
the patients and their relatives. Unfortunately, the diag-
nosis is often difficult to confirm in elderly patients with
a history of affective disorder. Especially in these pa-
tients, there is a considerable risk of missing a poten-
tially reversible condition such as a major depressive or
bipolar disorder [16].
In this case study, we describe a patient with type 1 bipo-
lar disorder, a dystonic movement disorder and severe
cognitive impairment who met the diagnostic criteria for
dementia. Eventually, however, the dementia appeared to
be largely reversible. We conclude that it is highly likely
that the dementia was the result of a depressive episode in
combination with the use of psychotropic drugs.Case presentation
A 60-year-old white female patient was referred to our
tertiary care hospital for a second opinion regarding a
severe treatment-resistant depression and a dystonic
movement disorder. She was first referred to the depart-
ment of psychiatry. Because she also suffered from severe
cognitive problems, she was subsequently referred to the
department of neurology. After extensive neurologic
evaluation she was referred back to the department of
psychiatry.
Her medical history included a type 1 bipolar disorder
since the age of eighteen years, with frequent manic and
depressive episodes and frequent admissions. Between
manic and depressive episodes, she was functioning well
and worked as a social worker. The last manic episode
before the current episode was in 1992. After this epi-
sode, she had been stable on a combination of lithium
and carbamazepine for eighteen years.
In May 2010, the current disease episode started with
manic symptoms. In that period, carbamazepine was
discontinued because of a confirmed allergic reaction. It
is possible that this event caused the manic episode. In
December 2010, this was followed by severe depressive
symptoms and psychosis. She was treated with different
combinations of antipsychotics (quetiapine, risperidone,
aripiprazole), mood stabilizers (lamotrigine, topiramate,
valproic acid) and antidepressants (clomipramine), with-
out any effect on symptoms. Lithium was discontinued
after an emergency admission for lithium intoxication.
In November 2011, the patient was treated with electro-
convulsive therapy (ECT), also without improvement of
the symptoms. During this period, she was admitted to a
regional psychiatric hospital several times. In January
2012, her symptoms worsened and she developed a
severe movement disorder with dyskinesia and frequent
falling. These complaints improved after reduction of
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biperiden and quetiapine). In the last months before
transfer to our hospital, her husband noticed progressive
memory problems, especially in the short-time memory.
In February 2012, the Mini-Mental State Examination
(MMSE) score was 12 (Figure 1). Neuropsychological
testing at that time was impossible because she was very
disorientated and not cooperative.
In October 2012, the patient was admitted to our
tertiary hospital to further evaluate her depressive episode
and cognitive problems. As common antidepressant treat-
ments seemed to be ineffective and memory impairment
progressed, we considered an underlying neurodegenera-
tive disease as the main cause of her complaints. At that
moment, she used lithium 500 mg a day and temazepam
10 mg a day as psychotropic medication. Furthermore, sheFigure 2 Magnetic resonance imaging scan of the brain. A, transverse
inversion recovery image; D, coronal T2-weighted image of the medial tem
1-2 with mild atrophy of the hippocampus (medial temporal lobe atrophy
to a magnetic resonance imaging scan performed one year earlier, there w
images showed some punctuate subcortical hyperintensities but no otherused levothyroxin, nifedipine, nebivolol and alfacalcidol
because of hypothyreoidism, hypertension and renal
impairment, respectively. At admission, we saw a thin,
anxious woman. Her consciousness was clear. Orienta-
tion in time and place was disturbed. She had difficulty
with speech due to orofacial dyskinesia. Her MMSE
score at that time was 11/30 points (Figure 1). During
her stay, it was observed that she clearly had memory
problems and could not find her way on the ward. She
also had great difficulty in executive functioning tasks
such as cooking and there were signs of apraxia. She
was not able to dress and wash herself. In addition, she
suffered from hallucinations and delusional ideas which
were nihilistic in nature.
The differential diagnosis included neurodegenerative
disease or cognitive impairment as the result of severeT1-weighted image; B and C, transverse T2-weighted fluid attenuated
poral lobe and hippocampus. There was global cortical atrophy grade
score, 1-2), on the left more pronounced than on the right. Compared
as no progression of these features. Furthermore, the T2-weighted
focal structural changes.
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was very severe we decided to perform additional diag-
nostic investigations for neurodegenerative disease
such as neuroimaging and CSF analysis. However, the
results of the magnetic resonance imaging (MRI) scan
and 18 F-fluoro-deoxy-glucose positron emission tom-
ography (FDG-PET) scan of the brain did not match
classic patterns of known neurodegenerative causes
(Figures 2 and 3). In combination with the negative
results of the cerebrospinal fluid (CSF) analysis (Table 1),
it seemed unlikely that her cognitive impairment was
caused by a neurodegenerative disease.
We decided to treat the patient for a severe depressive
episode with psychotic features. After careful evaluation
of prior medication use, we started with nortriptylin with
monitoring of the serum levels. In the following months,
we saw a slow but significant improvement of her mood
disorder and cognitive functioning. The MMSE score
improved to 29 points (Figure 1). Also, the severe move-
ment disorder improved to minimal orofacial dyskinesia.
The patient was able to perform activities of daily living
as well as cooking and gardening independently.
Conclusions
In clinical practice, doctors often see elderly patients with
depressive symptoms and cognitive impairment. Differ-
entiating between a major depression with cognitiveFigure 3 18 F-fluoro-deoxy-glucose positron emission tomography sc
of hypometabolism of the right parietal cortex (white arrow) and tempora
hemisphere (yellow arrow). The latter could not be explained by crossed cere
shown a hypometabolic pattern.symptoms and early dementia is a great challenge [17].
Depression or feelings of sadness can be the first symp-
tom of a neurodegenerative disease, whereas memory
complaints and other cognitive impairments can be part
of a depressive disorder. In the past, cognitive impair-
ment due to depressive disorder was called pseudode-
mentia and there is a widespread belief that it can be
improved by antidepressive treatment. However, evi-
dence is scarce and often of low quality, due to small
numbers of patients and the lack of randomized trials.
Improvement of cognitive impairment following anti-
depressive treatment has been reported in the literature
[18]. The review of Tielkes et al. and the meta analysis
of Semkovska et al., describe a statistical significant
effect of ECT on cognitive performance [10,11]. However,
the effects are small and only measured as change in
MMSE score. In a retrospective study, a mean improve-
ment of 1.62 points on the MMSE score was measured
[19]. In several prospective studies, no significant differ-
ence on MMSE score was measured [20,21]. Unfortu-
nately, all studies were relatively small and in some studies
patients with dementia (MMSE <24) were excluded.
Wagner et al. describe a patient with dementia and an
MMSE score of 21 points, who suffered from a unipolar
depression. After five ECT sessions, his MMSE score
had improved to 28 points. However, cognitive impair-
ment in this patient was relatively mild compared toan of the brain (transverse images). There was a non-specific pattern
l cortex (red arrow) as well as hypometabolism of the right cerebellar
bellar diaschisis as in that case the left cerebellar hemisphere would have
Table 1 Results of relevant laboratory tests
Laboratory test Result Reference value
Leucocytes, ×109/L 6.5 4.0-10.0
Hemoglobin, mmol/L 8.3 7.5-9.9
MCV, fL 91 80-96
Thrombocytes, ×109/L 196 150-350
CRP, mg/L <5 <5
Serum creatinine, umol/L 105 <90
Calcium, mmol/L 2.53 2.20-2.60
Total protein, g/L 68 60-80
Albumin, g/L 46 35-50
Glucose mmol/L 5.2 4.4-5.5
Folic acid, nmol/L 19 4.0-30.0
Vitamin B12, pmol/L 412 145-450
Thyroid-stimulating homone, mE/L 2,6 0.5-4.0
Lithium, mmol/L 0.66 0.6-1.2
CSF
Protein, mg/L 250 290-670
Glucose, mmol/L 2.8 2.2-4.4
Erythrocytes, ×106/L 0 absent
Leukocytes, ×106/L 1 <5
Beta-amyloid, pg/mL 968 >500
Total-tau, pg/mL 180 0-350
Phosphorylated-tau, pg/mL 43 <85
Paraneoplastic antibodies negative negative
Abbreviations: CRP, C-reactive protein; CSF, Cerebrospinal fluid; MCV, Mean
corpuscular volume.
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evidence of improvement in MMSE performance with
other treatments than ECT.
Our patient had more severe cognitive impairment
than any other patient described in the literature.
Usually, such severe symptoms are caused by a neuro-
degenerative disease. However, despite extensive evalu-
ation, we could not find any other evidence that
supported the diagnosis of a neurodegenerative disease.
The patient improved solely on a low dose of nortripty-
line in addition to the restart of lithium and discontinu-
ation of antipsychotic medication which is highly unlikely
in case of a neurodegenerative disease. Although she did
not completely improve to her premorbid level of func-
tioning, improvement was striking and of great value for
the patient and her family.
We assume that the severe cognitive symptoms at
admission, were a combination of major depressive dis-
order with psychotic features, and the adverse effects
of medication (mainly antipsychotics). The remaining
cognitive deficits could be explained in the light of herlong existent bipolar disorder with frequent manic and
depressive episodes in the past and the long duration of
her last episode. This has been previously described in
the literature [12-14,22,23]. There is little evidence that
lithium causes cognitive impairment [24].
The prominent movement disorder was probably drug
induced dyskinesia and akathasia [25]. These complaints
diminished after discontinuation of antipsychotic drugs.
Although these movement disorders are well known side
effects of antipsychotic drugs, they can also be a symp-
tom in several neurodegenerative diseases. Therefore, we
advocate that in the evaluation of movement disorders
and neurodegenerative diseases, medication is carefully
reviewed and stopped if possible.
Although convincing evidence regarding improvement
of dementia due to depression is scarce, our case shows
the remarkable recovery of severe cognitive impairment in
a depressed 60-year-old woman. Although it took several
months before her depressive and cognitive symptoms
improved, the treatment of her symptoms was relatively
simple with little to no side effects. In our opinion, this
proves that improvement in individual cases is possible
and underlines the necessity of careful re-evaluation
of medical history and medication use. Without this
re-evaluation, there is a considerable risk of missing a
potentially reversible condition with great implications
for the patient and his or her relatives.
Finally, in the fifth edition of the Diagnostic and Stat-
istical Manual of Mental Disorders (DSM-5) that was
recently published by the American Psychiatric Associ-
ation (APA), the term dementia was replaced with the
term major neurocognitive disorder [15]. We think that
our case study illustrates the advantages of this new
term. Although physicians and patients may be accus-
tomed to the term dementia, dementia is generally asso-
ciated with neurodegenerative and cerebrovascular
diseases that have a progressive course and cannot be
reversed or cured. As a consequence, the term revers-
ible dementia easily leads to confusion. Furthermore, a
considerable number of persons aged <70 years are
diagnosed with dementia that is caused by nondegen-
erative, nonvascular diseases [9]. Therefore, in our opin-
ion, major neurocognitive disorder is the preferred term
used when referring to persons aged <70 years with
severe cognitive deficits that are caused by nondegen-
erative, nonvascular diseases and may be amenable to
curative treatment.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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